Evidence map›Paper›PMID 30152151›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2019

Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.

N Groot, D Shaikhani, Y K O Teng, K de Leeuw, M Bijl, R J E M Dolhain, E Zirkzee, R Fritsch-Stork, I E M Bultink, S Kamphuis

Open access · bronzeAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 4 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 4 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Observational
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Neuropsychiatric Systemic Lupus Erythematosus in Children: A Scoping Review.Open access rheumatology : research and reviews · 2026
    Review
  17. Article
  18. Review
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

N GrootSophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands, and Wilhelmina Children's Hospital, University Medical Center, Utrecht, The Netherlands.
D ShaikhaniSophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands.
Y K O TengLeiden University Medical Center, Leiden, The Netherlands.
K de LeeuwUniversity Medical Center, Groningen, The Netherlands.
M BijlMartini Hospital, Groningen, The Netherlands.
R J E M DolhainErasmus University Medical Center, Rotterdam, The Netherlands.
E ZirkzeeMaasstad Hospital, Rotterdam, The Netherlands.
R Fritsch-StorkUniversity Medical Center, Utrecht, The Netherlands, Hanusch Hospital of WGKK and AUVA Trauma Center, Vienna, Austria, and Sigmund Freud University, Vienna, Austria.
I E M BultinkAmsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5441-3420
S KamphuisSophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands.
Erasmus MC · NLAmsterdam University Medical Centers · NLLeiden University Medical Center · NLMaasstad Ziekenhuis · NLMartini Ziekenhuis · NLSigmund Freud Privatuniversität Wien · ATUniversity Medical Center Groningen · NL

Funding

Dutch Arthritis Foundation BP12-1-261Dutch Kidney Foundation 17OKG04Dutch Kidney Foundation KJPB12.028National Association for LUPUS, APS, Scleroderma and MCTD (NVLE)Netherlands Organization for Scientific Research 90713460
6 · The paper itself

Abstract

objectiveChildhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease. Long-term outcome data are limited. This study was undertaken to identify clinical characteristics and health-related quality of life (HRQoL) of adults with childhood-onset SLE.

methodsPatients participated in a single study visit comprising a structured history and physical examination. Disease activity (scored using the SLE Disease Activity Index 2000 [SLEDAI-2K]), damage (scored using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index [SDI]), and HRQoL (scored using the Short Form 36 Health Survey) were assessed. Medical records were reviewed.

resultsIn total, 111 childhood-onset SLE patients were included; the median disease duration was 20 years, 91% of patients were female, and 72% were white. Disease activity was low (median SLEDAI-2K score 4), and 71% of patients received prednisone, hydroxychloroquine (HCQ), and/or other disease-modifying antirheumatic drugs. The vast majority of new childhood-onset SLE-related manifestations developed within 2 years of diagnosis. Damage such as myocardial infarctions began occurring after 5 years. Most patients (62%) experienced damage, predominantly in the musculoskeletal, neuropsychiatric, and renal systems. Cerebrovascular accidents, renal transplants, replacement arthroplasties, and myocardial infarctions typically occurred at a young age (median age 20 years, 24 years, 34 years, and 39 years, respectively). Multivariate logistic regression analysis showed that damage accrual was associated with disease duration (odds ratio [OR] 1.15, P < 0.001), antiphospholipid antibody positivity (OR 3.56, P = 0.026), and hypertension (OR 3.21, P = 0.043). Current HCQ monotherapy was associated with an SDI score of 0 (OR 0.16, P = 0.009). In this cohort, HRQoL was impaired compared to the overall Dutch population. The presence of damage reduced HRQoL scores in 1 domain. High disease activity (SLEDAI-2K score ≥8) and changes in physical appearance strongly reduced HRQoL scores (in 4 of 8 domains and 7 of 8 domains, respectively).

conclusionThe majority of adults with childhood-onset SLE in this large cohort developed significant damage at a young age and had impaired HRQoL without achieving drug-free remission, illustrating the substantial impact of childhood-onset SLE on future life.

Indexed as

Quality of LifeAdolescentAdultAgedAge of OnsetAntibodies, AntiphospholipidAntirheumatic AgentsChildChild, PreschoolFemaleGlucocorticoidsHumansHydroxychloroquineHypertensionKidney TransplantationLogistic ModelsAntibodies, AntiphospholipidAntirheumatic AgentsGlucocorticoidsHydroxychloroquinePrednisone

Identifiers

PMID30152151
PMCPMC6590133
OpenAlexW2889151930

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.